Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus XACIATO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus XACIATO.
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs XACIATO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin, which reversibly binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation. It exhibits primarily bacteriostatic activity against susceptible gram-positive cocci and anaerobes.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby preventing peptide bond formation.
Clindamycin 600-2700 mg/day IV divided every 6-8 hours. For severe infections, up to 4800 mg/day IV may be given.
Administer one vaginal gel (50 mg clindamycin) intravaginally as a single dose.
None Documented
None Documented
The terminal elimination half-life is approximately 2.4-3.0 hours in adults with normal renal and hepatic function; prolonged to 3-6 hours in hepatic impairment and up to 8-14 hours in severe hepatic disease.
Terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. Half-life may be prolonged in patients with severe hepatic impairment or neonates.
Clindamycin is primarily eliminated via hepatic metabolism; approximately 10% is excreted unchanged in urine, 3.6% in feces, and the remainder as inactive metabolites in bile and urine.
Clindamycin is primarily excreted via bile (approximately 85% of the dose as metabolites and parent drug) and feces (10%), with renal excretion accounting for less than 10%.
Category C
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic